The results indicated that late treatment with anti-PVRIG mAb significantly inhibited tumor growth (P < 0.0001; Fig. 4g) and prolonged the overall survival of tumor-bearing mice (P < 0.01; Fig. 4h). Here, PVRIG is linked to neoplasm.